Yuanli Chen Selected Research

buchang naoxintong

1/2017	NaoXinTong Enhances Atorvastatin-induced Plaque Stability While Ameliorating Atorvastatin-induced Hepatic Inflammation.
3/2016	NaoXinTong Inhibits the Advanced Atherosclerosis and Enhances the Plaque Stability in Apolipoprotein E Deficient Mice.
1/2015	NaoXinTong Inhibits the Development of Diabetic Retinopathy in db/db Mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yuanli Chen Research Topics

Disease

31	Atherosclerosis 01/2022 - 06/2012
18	Inflammation (Inflammations) 01/2022 - 04/2014
8	Fatty Liver 01/2022 - 01/2018
8	Neoplasms (Cancer) 12/2021 - 06/2013
6	Insulin Resistance 01/2021 - 01/2019
5	Vascular Calcification 01/2022 - 10/2018
5	Non-alcoholic Fatty Liver Disease 01/2021 - 02/2018
4	Fibrosis (Cirrhosis) 04/2022 - 11/2019
4	Lung Injury 01/2022 - 01/2016
4	Sepsis (Septicemia) 01/2022 - 01/2016
4	Cardiovascular Diseases (Cardiovascular Disease) 01/2021 - 01/2015
4	Carcinoma (Carcinomatosis) 01/2021 - 04/2014
4	Breast Neoplasms (Breast Cancer) 12/2018 - 05/2015
4	Coronary Disease (Coronary Heart Disease) 01/2017 - 05/2014
3	Obesity 01/2022 - 01/2020
3	Osteoradionecrosis 12/2021 - 01/2015
3	Cholestasis 03/2021 - 01/2019
3	Cerebrovascular Disorders (Cerebrovascular Occlusion) 01/2021 - 01/2018
3	Thrombosis (Thrombus) 01/2021 - 01/2018
3	Vascular Diseases (Vascular Disease) 03/2020 - 01/2019
3	Dyslipidemias (Dyslipidemia) 01/2020 - 04/2015
3	Hypertriglyceridemia 01/2020 - 04/2015
2	Atherosclerotic Plaque (Atheroma) 01/2022 - 01/2020
2	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 01/2022 - 01/2022
2	Atrophy 03/2021 - 01/2021
2	Hyperlipidemias (Hyperlipidemia) 01/2021 - 12/2018
2	Neuroinflammatory Diseases 01/2021 - 05/2020
2	Heart Failure 12/2020 - 03/2020
2	B-Cell Lymphoma (Lymphoma, B Cell) 12/2020 - 01/2020
2	Liver Cirrhosis (Hepatic Cirrhosis) 12/2020 - 11/2019
2	Acute Lung Injury 12/2020 - 01/2018
2	Body Weight (Weight, Body) 12/2020 - 06/2015
2	Hypercholesterolemia 11/2020 - 01/2017
2	Infections 07/2020 - 12/2018
2	Necrosis 01/2020 - 11/2019
2	Diabetic Nephropathies (Diabetic Nephropathy) 10/2019 - 01/2018
2	Hemorrhage 01/2019 - 01/2016
2	Neoplasm Metastasis (Metastasis) 12/2018 - 01/2016

Drug/Important Bio-Agent (IBA)

17	Apolipoproteins E (ApoE)IBA 01/2022 - 04/2015
12	LipidsIBA 01/2022 - 06/2013
9	LigandsIBA 01/2022 - 12/2012
9	Capsules (Microcapsules)IBA 01/2021 - 01/2015
9	Liver X ReceptorsIBA 01/2021 - 12/2012
7	T0901317IBA 01/2021 - 04/2014
7	naoxintongIBA 01/2021 - 01/2015
6	CholesterolIBA 01/2019 - 12/2012
5	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2018
5	U 0126 (UO 126)IBA 01/2022 - 02/2015
5	Transcription Factors (Transcription Factor)IBA 06/2021 - 12/2012
5	CollagenIBA 03/2021 - 05/2015
4	ApolipoproteinsIBA 01/2022 - 05/2014
4	Therapeutic UsesIBA 01/2022 - 01/2019
4	CytokinesIBA 01/2022 - 01/2018
4	InterferonsIBA 01/2022 - 02/2015
4	Rosiglitazone (Avandia)FDA Link 01/2021 - 11/2019
4	Glucose (Dextrose)FDA LinkGeneric 12/2020 - 06/2015
4	LongShengZhiIBA 03/2020 - 01/2019
4	oxidized low density lipoproteinIBA 01/2020 - 12/2012
3	Antiviral Agents (Antivirals)IBA 01/2022 - 12/2018
3	Adenosine Monophosphate (AMP)IBA 01/2022 - 02/2018
3	Small Interfering RNA (siRNA)IBA 01/2022 - 05/2020
3	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2022 - 03/2020
3	Collagen Type I (Type I Collagen)IBA 03/2021 - 11/2019
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 03/2021 - 11/2019
3	Transforming Growth Factors (Transforming Growth Factor)IBA 03/2021 - 11/2019
3	Pharmaceutical PreparationsIBA 01/2021 - 06/2015
3	Tamoxifen FDA LinkGeneric 12/2018 - 05/2015
3	trioctyl phosphine oxide (TOPO)IBA 12/2018 - 06/2013
3	Teniposide (VM 26)FDA Link 12/2018 - 06/2013
3	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 02/2018 - 08/2015
3	buchang naoxintongIBA 01/2017 - 01/2015
3	Fatty Acid-Binding ProteinsIBA 08/2015 - 06/2012
2	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2022 - 12/2020
2	Biological ProductsIBA 01/2022 - 01/2021
2	Pentoxifylline (Trental)FDA LinkGeneric 12/2021 - 01/2020
2	Vitamin E FDA LinkGeneric 12/2021 - 01/2020
2	Toll-Like Receptor 4IBA 03/2021 - 01/2021
2	Glutathione PeroxidaseIBA 03/2021 - 01/2020
2	CatalaseIBA 03/2021 - 03/2020
2	Bile Acids and Salts (Bile Acids)IBA 03/2021 - 01/2019
2	Triglycerides (Triacylglycerol)IBA 01/2021 - 01/2019
2	Fenofibrate (CiL)FDA LinkGeneric 01/2021 - 01/2019
2	Urethane (Ethyl Carbamate)IBA 01/2021 - 01/2016
2	Metformin (Glucophage)FDA LinkGeneric 01/2021 - 01/2018
2	HydrogelsIBA 01/2021 - 01/2021
2	Glutamic Acid (Glutamate)FDA Link 01/2021 - 01/2020
2	Peptides (Polypeptides)IBA 01/2021 - 12/2020
2	LDL Receptors (LDL Receptor)IBA 01/2021 - 05/2014
2	Doxorubicin (Adriamycin)FDA LinkGeneric 12/2020 - 03/2020
2	AdiponectinIBA 12/2020 - 01/2017
2	asparaginyl- isoleucyl- prolyl- norvalyl- leucyl- tyrosyl- seryl- phenylalanyl- alanyl- serinamideIBA 12/2020 - 01/2017
2	Analgesics (Analgesic Drugs)IBA 05/2020 - 06/2015
2	formononetinIBA 01/2020 - 01/2019
2	IsoflavonesIBA 01/2020 - 01/2019
2	Biomarkers (Surrogate Marker)IBA 01/2020 - 01/2018
2	CarrageenanIBA 01/2019 - 01/2018

Therapy/Procedure

6	Chinese Traditional Medicine (Traditional Chinese Medicine) 01/2021 - 01/2018
6	Therapeutics 01/2021 - 04/2015
3	Ligation 11/2019 - 01/2016
2	Oral Administration 01/2021 - 01/2021